LAVA Therapeutics NV Logo

LAVA Therapeutics NV

Develops bispecific gamma delta T cell engagers for solid and hematologic cancers.

LVTX | NDAQ

Overview

Corporate Details

ISIN(s):
NL0015000AG6
LEI:
Country:
United States of America
Address:
YALELAAN 62, 0 UTRECHT
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

LAVA Therapeutics NV is a clinical-stage immuno-oncology company developing treatments for cancer. The company's proprietary Gammabody® platform generates novel bispecific gamma delta T cell engager (bsTCE) therapeutics. This approach is designed to activate and direct a unique and abundant subset of immune effector cells, called Vγ9Vδ2 T cells, to tumors. The mechanism aims to selectively kill cancer cells and trigger a durable, cascading immune response. LAVA's portfolio of drug candidates targets both solid tumors and hematologic malignancies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all LAVA Therapeutics NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for LAVA Therapeutics NV

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for LAVA Therapeutics NV via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America APRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.